Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Belantamab mafodotin (Primary) ; Elotuzumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 04 Jun 2024 Results (As of January 20, 2024, n=12) from phase I part of this trial, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 13 Nov 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2026.
- 13 Nov 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Jan 2025.